FDA Expands Quanterix’s COVID-19 Antigen Test Emergency Use Label
The FDA has expanded the Emergency Use Authorization (EUA) label for Quanterix Corporation’s (NASDAQ:QTRX) Simoa SARS-CoV-2 N Protein Antigen Test. The expanded…
Return On Capital Employed Insights For Quanterix
Benzinga Pro data, Quanterix (NASDAQ:QTRX) reported Q2 sales of $25.37 million. Earnings fell to a loss of $13.67 million, resulting in a 39.63% decrease from last quarter.
Why Cassava Sciences Stock Investors Are Pulling Back
The neurodegenerative diseases-focused biopharma Cassava Sciences, Inc. (NASDAQ: SAVA) has now lost half of its market capitalization.
Benzinga Pro’s Top 5 Stocks To Watch For Friday, Aug. 27, 2021: BABA, ZM, SAVA, SPRT, CHGG
Today's 5 Stock Ideas:
Alibaba (BABA) - Shares were lower Friday morning, likely on the heels of a WSJ article "China Plans to Ban U.S. IPOs for Data-Heavy Tech Firms."
Zoom Video
Quanterix In Statement Following Cassava Reports Says ‘Quanterix or its employees did not interpret the test results or prepare the data charts presented by Cassava at the Alzheimer’s Association International Conference (AAIC) in July 2021 or otherwis…
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today released the following statement in response to news reports related to Cassava
63 Biggest Movers From Yesterday
Gainers
Support.com, Inc. (NASDAQ: SPRT) shares surged 41.1% to settle at $19.70 on Thursday on abnormally high volume.
45 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Blue Water Acquisition Corp. (NASDAQ: BLUW) shares climbed 57% to $16.41. Blue Water Acquisition is expected to hold a special meeting of its stockholders on Friday, August 27, 2021.
Quanterix Highlights Eli Lilly’s Presentation Of Phase 2 TRAILBLAZER-ALZ Study Utilizing Quanterix’ Simoa HD-X
Ultra-sensitive Simoa® HD-X technology powers new findings that detect rapid reduction of plasma P-tau217 from donanemab, Lilly's investigational antibody therapy for Alzheimer's disease at 12
Quanterix Q2 Non-GAAP Loss $12.94M Down From $11.61M YoY
Quanterix (NASDAQ:QTRX) reported $12.94 million in sales this quarter. This is a 1.45 percent decrease over sales of $13.13 million the same period last year.
Canaccord Genuity Maintains Buy on Quanterix, Lowers Price Target to $75
Canaccord Genuity analyst Kyle Mikson maintains Quanterix (NASDAQ:QTRX) with a Buy and lowers the price target from $90 to $75.